Preliminary trials into Zorevunersen find drug to be safe and well tolerated by those with Dravet syndrome

Scientists have hailed a potentially life-changing drug for children with a hard to treat form of epilepsy, after promising early clinical trial results.

Dravet syndrome is a genetic disorder which causes treatment resistant epilepsy and is often accompanied by speech and developmental delays. About 3,000 people are thought to have the condition in the UK. Current treatments aim to control the number and severity of seizures, but often do not work.